When Is Rituximab Used for Antisynthetase Syndrome?

Rituximab (Rituxan) is an intravenous (IV) biologic medication that targets specific immune cells (CD20-positive B-cells) to reduce a component of autoimmune inflammation ^[1]. In antisynthetase syndrome, it is generally prescribed as an “off-label” treatment—meaning it is not specifically approved by regulators for this rare disease, but specialists consider it a viable option for severe, progressive, or treatment-refractory cases ^[2]. Treatment is highly individualized; there is no universally accepted sequence of medications, and decisions depend on which organs are involved, disease severity, and previous treatments ^[3].

When Is Rituximab Considered?

Specialists, such as rheumatologists and pulmonologists, often consider rituximab in the following scenarios:

• When Disease Progresses on Initial Treatments: Treatment typically begins with corticosteroids (like prednisone) and oral immunosuppressive medicines, such as mycophenolate mofetil or azathioprine ^[4]. If your lung function tests—such as Forced Vital Capacity (FVC, how much air you can exhale forcefully)—continue to decline, rituximab may be considered as an escalation or rescue therapy ^[5]. However, your doctor must first confirm that the decline or changes on a CT scan are due to active autoimmune inflammation, rather than permanent scarring (fibrosis), a respiratory infection, or medication side effects ^[5].
• Urgent, Rapidly Progressive Lung Disease: If interstitial lung disease (ILD) advances very quickly, it is a medical emergency that requires urgent assessment, often in a hospital ^[6]. In these acute cases, doctors may bypass oral medicines ^[7]. Because rituximab takes weeks to months to reach its full effect, it is often combined with high-dose IV corticosteroids or other fast-acting drugs to attempt to control the inflammation and reduce the risk of further lung damage ^[6]. If you experience rapidly worsening breathlessness, falling oxygen levels, chest pain, or a new inability to speak in full sentences, seek emergency medical care immediately.
• Treatment-Resistant Muscle Weakness: Antisynthetase syndrome can cause profound muscle inflammation (myositis). If significant weakness persists despite standard therapies, rituximab is one option to help manage the disease ^[8]. Doctors will evaluate whether the weakness is truly from active autoimmune myositis rather than permanent muscle damage, physical deconditioning, or muscle weakness caused by long-term steroid use (steroid-induced myopathy) ^[4].

What the Research Shows

Because antisynthetase syndrome is rare, much of the evidence for rituximab comes from small observational studies rather than large randomized trials ^[1].

• Lung Function: In small studies observing patients (typically 25 to 30 people) who received rituximab because their ILD was worsening, most patients saw their lung function and CT scans stabilize or improve over a year ^[1][5]. Some patients were able to significantly reduce their daily prednisone dose or stop using supplemental oxygen, though this improvement is not guaranteed for everyone, particularly if there is existing lung fibrosis ^[5].
• Comparisons to Other Treatments: A major clinical trial (the RECITAL trial) compared rituximab to cyclophosphamide—another powerful IV immunosuppressant with substantial risks—in patients with various connective tissue disease-related ILDs, though not exclusively antisynthetase syndrome ^[9]. Both drugs improved lung function similarly, but patients on rituximab had a lower overall corticosteroid exposure during the study ^[9].
• Combination Therapy: In some cases, doctors prescribe rituximab alongside an oral medicine like mycophenolate mofetil, as combination therapy has shown benefits for specific patterns of lung inflammation in trials ^[10]. However, this dual approach requires careful balancing, as it increases the risk of infections ^[10].
• Antibody Profiles: Research suggests that patients carrying high levels of an antibody called anti-Ro52 may be at risk for more aggressive lung disease ^[11]. While some small studies note these patients may respond to rituximab, anti-Ro52 positivity is a preliminary association and is not used alone to determine if rituximab is the right choice for an individual patient ^[11].

What to Expect: Logistics and Safety

Receiving rituximab involves coordinated care and close monitoring because it deeply suppresses a portion of your immune system.

• Pre-Treatment Checks: Before starting, your care team will screen you for active and past infections, including hepatitis B, as rituximab can cause dormant viruses to reactivate ^[10]. They will also check your baseline immunoglobulin (antibody) levels and blood counts ^[5].
• Vaccinations: Because rituximab impairs your body’s ability to make new antibodies, you should receive any necessary vaccines before starting treatment ^[10]. Live vaccines must generally be avoided while on the drug ^[10].
• The Infusion: Rituximab is given as an IV infusion, usually in two doses spaced two weeks apart, with potential repeat doses months later. You will receive premedications (like antihistamines or steroids) to prevent infusion reactions, and you will be monitored closely during the procedure.
• Infection Risk: The most significant risk is infection, including severe respiratory infections like pneumonia ^[6]. If you are taking rituximab alongside high-dose steroids, your doctor may prescribe an individualized daily antibiotic to prevent a specific opportunistic lung infection called Pneumocystis (PJP) ^[5]. Always contact your doctor promptly if you develop a fever, new cough, or worsening shortness of breath.